3-HO-PCP Stats & Data

3-HO-PCP was first synthesized in 1978 during investigations into the structure-activity relationships of phencyclidine (PCP) derivatives. Throughout the 1980s, researchers continued to characterize its pharmacological properties, discovering its activity at opioid receptors in animal models during this period. The compound remained largely unknown outside academic circles until 1999, when a chemist operating under the pseudonym "John Q. Beagle" discussed it in a post on The Hive, a now-defunct online chemistry forum. Beagle highlighted the compound's substantially increased potency compared to PCP and its notable affinity for opioid receptors. Even before the substance became commercially available, members of the Bluelight forum had begun documenting its psychoactive effects based on personal experimentation. Around 2009, 3-HO-PCP entered the research chemical market through online vendors. Despite being structurally related to PCP—a compound that had developed considerable notoriety through decades of media coverage and street names like "angel dust," "rocket fuel," and "sherm"—3-HO-PCP has remained one of the more obscure members of the arylcyclohexylamine class. It continues to be distributed primarily through gray-market online sources, with very little formal research having been conducted on its effects, metabolism, or toxicity in humans.

The toxicity and long-term health effects of recreational 3-HO-PCP use have not been studied in any scientific context and the exact toxic dosage is unknown. This is because 3-HO-PCP has an extremely brief history of human usage.

Effects aggregated from 12 experience reports (7 single-substance Erowid + 5 Bluelight)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 7 single-substance Erowid and 5 analyzed Bluelight reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Also reported in combinations. In the 10 3-HO-PCP reports where another drug was taken too, 2 mention hospital, emergency services or an overdose, 0 a seizure and 2 psychosis (too few reports for percentages). In the 7 single-substance reports: 0, 0 and 2. These are not in the figures above: they cannot be put down to 3-HO-PCP alone, and a mention is not always something that happened to the writer.

From 156 of 160 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Most co-occurring substances, as a share of all 17 reports filed under 3-HO-PCP

Too few reports for bars: these combinations come from 17 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• THC 3 of 17

Most common forms and preparations, as a share of the 13 reports that give one

Too few reports for bars: these forms come from 13 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• Powder / Crystals 7 of 13
• Liquid 5 of 13

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Redosing behavior across 13 reports